SLC5A2 and stage 5 chronic kidney disease: This directive facilitated large outcome trials confirming the class effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in reducing major adverse cardiovascular events as well as cardiorenal benefits, including reductions in heart failure hospitalizations and progression to end-stage renal disease in both diabetic and nondiabetic patients [15,16].